BACKGROUND: Different surgical strategies are used to treat medical refractory renal hyperparathyroidism. Our preferred choice in patients with moderate secondary hyperparathyroidism (SHPT) and in patients with low compliance with medical treatment is to leave a very small parathyroid remnant in situ: we name this operation "near total parathyroidectomy" (ntPTX). We report here our results with this technique. METHODS: Retrospective study [2001-2015] of all patients submitted to ntPTX in a single centre. RESULTS: Forty-seven patients were submitted to ntPTX (32 males) aged 47.3 years. Follow-up time is 8.5 years. Thirty-five patients (74%) are alive, 12 are dead. One patient in this series had a functioning renal transplant at time of ntPTX (tertiary hyperparathyroidism), and other 27 subsequently received a renal transplantation (RTx) after ntPTX (still functioning at last follow-up or at death in 19). Amongst the 35 current survivors, the renal graft is functioning in 16 (45.7%). Parathyroid hormone (PTH) at follow-up was 116.1±135.5 pg/mL and calcium 8.6±0.9 mg/dL. Among patients with a functioning RTx PTH was 83 pg/mL and calcium 8.7 mg/dL. There was no persistent disease, and 3 patients (6.4%) had a relapse of hyperparathyroidism at follow-up. CONCLUSIONS: ntPTX is associated to very satisfying rates of normal parathyroid function and of relapse of hyperparathyroidism (6.4%) at long term, either in case of RTx or of maintenance hemodialysis: the concept of "small amount" remnant represents a valuable choice for patients undergoing PTX with a realistic chance of receiving a RTx.
BACKGROUND: Different surgical strategies are used to treat medical refractory renal hyperparathyroidism. Our preferred choice in patients with moderate secondary hyperparathyroidism (SHPT) and in patients with low compliance with medical treatment is to leave a very small parathyroid remnant in situ: we name this operation "near total parathyroidectomy" (ntPTX). We report here our results with this technique. METHODS: Retrospective study [2001-2015] of all patients submitted to ntPTX in a single centre. RESULTS: Forty-seven patients were submitted to ntPTX (32 males) aged 47.3 years. Follow-up time is 8.5 years. Thirty-five patients (74%) are alive, 12 are dead. One patient in this series had a functioning renal transplant at time of ntPTX (tertiary hyperparathyroidism), and other 27 subsequently received a renal transplantation (RTx) after ntPTX (still functioning at last follow-up or at death in 19). Amongst the 35 current survivors, the renal graft is functioning in 16 (45.7%). Parathyroid hormone (PTH) at follow-up was 116.1±135.5 pg/mL and calcium 8.6±0.9 mg/dL. Among patients with a functioning RTx PTH was 83 pg/mL and calcium 8.7 mg/dL. There was no persistent disease, and 3 patients (6.4%) had a relapse of hyperparathyroidism at follow-up. CONCLUSIONS: ntPTX is associated to very satisfying rates of normal parathyroid function and of relapse of hyperparathyroidism (6.4%) at long term, either in case of RTx or of maintenance hemodialysis: the concept of "small amount" remnant represents a valuable choice for patients undergoing PTX with a realistic chance of receiving a RTx.
Authors: Katja Schlosser; Detlef K Bartsch; Markus K Diener; Christoph M Seiler; Tom Bruckner; Christoph Nies; Moritz Meyer; Jens Neudecker; Peter E Goretzki; Gabriel Glockzin; Ralf Konopke; Matthias Rothmund Journal: Ann Surg Date: 2016-11 Impact factor: 12.969
Authors: Katrin Uhlig; Jeffrey S Berns; Bryan Kestenbaum; Raj Kumar; Mary B Leonard; Kevin J Martin; Stuart M Sprague; Stanley Goldfarb Journal: Am J Kidney Dis Date: 2010-04-03 Impact factor: 8.860
Authors: Sarah C Oltmann; Tariq M Madkhali; Rebecca S Sippel; Herbert Chen; David F Schneider Journal: J Surg Res Date: 2015-04-18 Impact factor: 2.192
Authors: John Cunningham; Geoffrey A Block; Glenn M Chertow; Kerry Cooper; Pieter Evenepoel; Jan Iles; Yan Sun; Pablo Ureña-Torres; David A Bushinsky Journal: Kidney Int Rep Date: 2019-04-16